GRACE, TIMI, Zwolle and CADILLAC risk scores--do they predict 5-year outcomes after ST-elevation myocardial infarction treated invasively?

Autor: Kozieradzka A; Department of Cardiology, Medical University of Bialystok, ul. M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland. Anna.Kozieradzka@daad-alumni.de, Kamiński KA, Maciorkowska D, Olszewska M, Dobrzycki S, Nowak K, Kralisz P, Prokopczuk P, Musial WJ
Jazyk: angličtina
Zdroj: International journal of cardiology [Int J Cardiol] 2011 Apr 01; Vol. 148 (1), pp. 70-5. Date of Electronic Publication: 2009 Nov 18.
DOI: 10.1016/j.ijcard.2009.10.026
Abstrakt: Background: GRACE, TIMI, Zwolle, and CADILLAC are risk scores designed for predicting short-term outcome after acute coronary syndromes. The aim of our study was to test their utility for a prognosis of 5-year survival in a "real-life" population of patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary interventions (pPCI).
Methods: Our registry consisted of consecutive patients with STEMI treated with pPCI. Five-year follow-up was performed with all-cause mortality as the end-point.
Results: Out of 505 patients (mean age 58.6±11.3 years) 32 died during the first 30 days (6.3%) and an additional 74 within 5 years (15.6%). PCI was successful in 95.2% (n=481). Prognostic values (c statistics) for predicting 5-year mortality equaled: 0.742 (CI 0.69-0.79) for the GRACE risk score, 0.727 (CI 0.67-0.78) for TIMI, 0.72 (CI 0.67-0.77) for Zwolle, and 0.687 (CI 0.63-0.74) for CADILLAC. In a univariate analysis all the scores were associated with the 5-year outcome.
Conclusions: GRACE, TIMI, and Zwolle risk scores predicted well 5-year all-cause mortality in patients with STEMI treated with pPCI. Our data show that the usefulness of initial bedside risk assessment can be further extended for long-term follow-up.
(Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: